CMS Modified NCD 146 for EDTA Chelation Therapy, Effective March 7, 2026 — What Billing Teams Need to Know
TL;DR: The Centers for Medicare & Medicaid Services modified NCD 146, its national coverage determination for EDTA chelation therapy used to treat atherosclerosis and related conditions, effective March 7, 2026. The policy position is unchanged — this therapy remains non-covered and classified as experimental — but billing teams should treat this modification as a prompt to audit claims and educate clinical staff before they generate denials.
The CMS EDTA chelation therapy coverage policy under NCD 146 in the Medicare system has been formally updated. If your practice bills for chelation services — in cardiology, integrative medicine, or any specialty where EDTA infusions appear on the charge sheet — this update is your signal to review every workflow that touches these claims. No specific CPT or HCPCS codes are listed in the current policy document, which creates its own set of problems for billing teams, and we'll get into that.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Ethylenediamine-Tetra-Acetic (EDTA) Chelation Therapy for Treatment of Atherosclerosis |
| Policy Code | NCD 146 |
| Change Type | Modified |
| Effective Date | March 7, 2026 |
| Impact Level | Medium — financial exposure is high for practices that bill chelation routinely; low if you've never touched these claims |
| Specialties Affected | Cardiology, integrative medicine, internal medicine, infusion therapy |
| Key Action | Audit any chelation therapy charges billed to Medicare and confirm your team understands this is a hard non-coverage position — no prior authorization will save these claims |
CMS EDTA Chelation Therapy Coverage Criteria and Medical Necessity Requirements 2026
Here's the short version: there are no medical necessity criteria that make EDTA chelation therapy covered under Medicare for atherosclerosis, arteriosclerosis, calcinosis, or similar conditions. CMS does not cover it. Full stop.
The NCD 146 coverage policy language is direct. The use of EDTA as a chelating agent to treat atherosclerosis, arteriosclerosis, calcinosis, or similar generalized conditions not approved by the FDA is explicitly classified as experimental. CMS will not reimburse these services for Medicare beneficiaries.
This is not a "coverage with evidence development" situation. There is no pathway where you document medical necessity thoroughly enough and get the claim paid. The policy closes that door before you knock on it.
The distinction matters because billing teams sometimes treat "not covered" as a documentation problem. They assume a better prior auth submission or stronger clinical notes will flip the outcome. With NCD 146, that assumption leads directly to claim denial and potential compliance exposure. If a provider is ordering EDTA chelation for Medicare patients with atherosclerosis, the billing issue is secondary to a larger clinical and compliance conversation.
Whether prior authorization is required is almost a moot point here — no prior auth process exists for a service CMS has categorically excluded. If your team is asking whether you need prior authorization for EDTA chelation therapy under Medicare, the real answer is that prior auth wouldn't help. The service is non-covered under any circumstance for these diagnoses.
CMS EDTA Chelation Therapy Exclusions and Non-Covered Indications
NCD 146 is essentially an exclusion policy. Every indication listed in the policy falls into the non-covered category.
The conditions CMS explicitly calls out as non-covered are atherosclerosis, arteriosclerosis, calcinosis, and "similar generalized conditions." That last phrase — "similar generalized conditions" — is vague by design. CMS is signaling that the exclusion isn't limited to the named diagnoses. If a provider tries to reframe the clinical indication using a related but slightly different ICD-10 code, the policy language supports denying that too.
The FDA approval angle is also worth noting. The policy ties non-coverage directly to the absence of FDA approval for these uses. EDTA does have legitimate FDA-approved applications — certain types of heavy metal poisoning, for example. Those uses are a separate matter and governed by different coverage determinations. NCD 146 is narrowly focused on the cardiovascular and calcification indications that are not FDA-approved.
This is not an ambiguous policy. If your compliance officer asks whether there's any gray area in NCD 146, the answer is no. The policy is clear that any use of EDTA for these conditions is considered experimental by CMS. The clinical literature behind chelation therapy for cardiovascular disease is contested, but CMS's coverage policy is not.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Atherosclerosis treated with EDTA chelation | Not Covered — Experimental | No codes listed in policy | Hard exclusion; no medical necessity override applies |
| Arteriosclerosis treated with EDTA chelation | Not Covered — Experimental | No codes listed in policy | Same categorical exclusion |
| Calcinosis treated with EDTA chelation | Not Covered — Experimental | No codes listed in policy | Explicitly named in NCD 146 |
| Similar generalized cardiovascular/calcification conditions treated with EDTA | Not Covered — Experimental | No codes listed in policy | Broad language; CMS intends this to cover analogous diagnoses |
CMS EDTA Chelation Therapy Billing Guidelines and Action Items 2026
The effective date of March 7, 2026 makes this active now. Here's what your billing team should do.
| # | Action Item |
|---|---|
| 1 | Pull any EDTA chelation claims billed to Medicare in the last 12 months. Review them for diagnosis codes and place of service. If those claims were paid, flag them for your compliance officer — reimbursement on a categorically non-covered service creates overpayment risk. |
| 2 | Audit your charge master for chelation therapy line items. If EDTA infusion services appear without a hard Medicare billing block, add one. Your charge capture system should prevent these from going to Medicare without a deliberate override and ABN process in place. |
| 3 | Issue an Advance Beneficiary Notice (ABN) if the provider insists on billing. If a Medicare patient requests EDTA chelation for a cardiovascular condition and the provider agrees to perform it, an ABN must be issued before the service. This shifts financial liability to the patient and protects the practice from a claim denial turning into a compliance issue. Skipping the ABN means you can't bill the patient either. |
| 4 | Educate clinical staff — especially in integrative medicine and infusion therapy — about NCD 146. Providers who order EDTA chelation may not know that Medicare has a hard non-coverage position. The March 7, 2026 modification is a reason to schedule a quick billing and compliance briefing. The policy hasn't changed substantively, but a policy modification is a documented trigger you can use to justify the training. |
| 5 | Review cross-reference NCD 20.21 in the NCD Manual. CMS directs readers to §20.21 of the NCD Manual for related guidance. If your practice deals with any chelation therapy billing — including for legitimate heavy metal toxicity indications — confirm that those claims are coded and documented to a separately covered NCD, not NCD 146. |
| 6 | Talk to your compliance officer if your practice has billed chelation therapy to Medicare and received payment. This is not a situation to handle at the billing team level. Potential overpayments tied to a non-covered service require a compliance review and possibly a voluntary refund through CMS's self-disclosure protocols. Get your compliance officer involved before March 7, 2026 if this applies to you. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for EDTA Chelation Therapy Under NCD 146
A Note on Code Availability
The NCD 146 policy document as modified does not list specific CPT or HCPCS codes. This is a real problem for EDTA chelation therapy billing teams, and it deserves a direct explanation.
The absence of codes in the policy does not mean EDTA chelation therapy is uncodeable. It means CMS has not enumerated specific codes within the NCD itself. In practice, chelation therapy infusions are typically billed using infusion administration codes — but those codes also apply to covered infusion services. The denial logic for EDTA chelation claims will typically be driven by the diagnosis code combination and the specific drug billed, not a hard edit on a procedure code alone.
This creates a claim denial risk that's harder to catch on the front end. A billing system that blocks procedure codes won't catch a chelation claim if the procedure code is the same as a legitimate infusion. Your payers — including your Medicare Administrative Contractor — may apply edits at the drug or diagnosis level. Check with your MAC for any applicable local coverage determination guidance that supplements NCD 146.
Covered CPT Codes (When Selection Criteria Are Met)
No covered CPT or HCPCS codes are listed in this policy. There are no covered indications under NCD 146 for EDTA chelation therapy.
Not Covered / Experimental
| Code | Type | Description | Reason |
|---|---|---|---|
| Not specified in policy | — | EDTA chelation therapy for atherosclerosis, arteriosclerosis, calcinosis, and similar conditions | Experimental per NCD 146; no FDA-approved use for these indications |
Key ICD-10-CM Diagnosis Codes
No ICD-10 codes are specified in the NCD 146 policy document. ICD-10 codes that map to atherosclerosis (I70 range), arteriosclerosis, and calcinosis diagnoses are the relevant risk area. Work with your MAC or a billing consultant to identify the specific ICD-10 codes your team should flag for EDTA-related claim review.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.